{"allTrials": {"@totalCount": "5", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2009-09-28T00:00:00.000Z", "@version": "18", "isrctn": {"@dateAssigned": "2009-09-28T00:00:00.000Z", "#text": "76301727"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The incidence of residual prostate cancer in patients included in a randomised trial comparing hormonal treatment versus combination of hormonal treatment and radiotherapy in locally advanced prostate cancer", "scientificTitle": "Post-treatment prostatic biopsies after anti-androgen treatment with or without radiotherapy of locally advanced prostatic cancer: side study of the SPCG-7/SFUO-3 randomised trial", "acronym": null, "studyHypothesis": "The incidence of residual local tumour in prostatic biopsies from patients with locally advanced prostatic cancer following 3 years (and 6 months) hormonal treatment with flutamide, is not statistically different from the incidence seen in patients treated with radiotherapy and flutamide.\n\nPlease note that this is a side-study to a previously registered trial, which can be found under ISRCTN01534787 - \"A randomised trial comparing hormonal treatment versus combination of hormonal treatment and radiotherapy in locally advanced prostate cancer [SPCG-7/SFUO-3 trial]\" (http://www.controlled-trials.com/ISRCTN01534787).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "To compare the incidence of residual local tumour following hormonal treatment with the analogue incidence rate after the combination of hormonal treatment and radiotherapy. The incidence of residual prostate cancer was measured by post-treatment prostate biopsies performed 3 years plus/minus 6 months from randomisation in the SPCG-7/SFUO-3 trial.", "secondaryOutcome": "1. To study the prognostic implication of post-treatment residual tumour in patients included in SPCG-7. The prognostic implications of residual cancer were measured with respect to the following events:\n1.1. PSA-recurrence\n1.2. Local recurrence (clinical)\n1.3. Distant recurrence (metastasis)\n1.4. Death\nThese were measured as follows: All patients were followed by the the treating physician every 6 months from randomisation in the SPCG-7/SFUO-3 trial, and data with respect to these events was registered in the SPCG-7/SFUO-3 case report file (CRF) on every visit. In patients who had died, the cause of death was registered in the CRF. By the end of February 2008 survival status was controlled against the nation-wide population registries in Sweden and Norway.\n2. To obtain a storage of post-treatment biopsies for the possibility of further characterisation of residing tumour cells by means of immunohistochemical staining methods for potential prognostic markers. A storage of post-treatment prostate biopsies for the possibility of further characterisation of residing tumour cells was obtained at the time of biopsy (3 years plus/minus 6 months from randomisation in the SPCG-7/SFUO-3 trial).", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "The Regional Committee for Medical and Health Research Ethics of Middle-Norway approved on the 15th August 2000 (ref: 112-2000)"}, "externalRefs": {"doi": "10.1186/ISRCTN76301727", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Side-study to a randomised open comparative parallel-design trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2001-03-01T00:00:00.000Z", "overallEndDate": "2005-10-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Norway", "Sweden"]}, "trialCentres": {"trialCentre": {"@id": "d35d00d7-aee3-4585-a86e-6b682798e804", "name": "St. Olavs Hospital", "address": null, "city": "Trondheim", "state": null, "country": "Norway", "zip": "7006"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients must have been included in the SPCG-7/SFUO-3 study with the following inclusion criteria:\n1.1. Men less than 76 years of age and, as judged by the doctor, a life expectancy of less than 10 years (except for cancer) at time of randomisation with performance status World Health Organization (WHO) 0 - 2 \n1.2. Patients with histologically/cytologically verified prostatic cancer \n1.3. Patients with prostatic cancer of clinical category T1b-T2; G2-G3 and T3; G1-G3 according to the TNM classification system of 1992. Inclusion of patients with T1b-T2; G3 and T2; G2 is optional. \n1.4. The patients should have no evidence of metastases by clinical investigation, bone scan or pulmonary x-ray \n1.5. Patients should be lymph node negative \n1.6. Patients should be suitable for radiotherapy and anti-androgen treatment \n2. Written patient informed consent\n3. WHO performance status (Zubrod) 0 - 1\n4. No medical hazard connected with the previous or the planned biopsy-procedure", "ageRange": "Adult", "gender": "Male", "targetEnrolment": "200", "totalFinalEnrolment": null, "totalTarget": "200 patients", "exclusion": "1. Patient refusal\n2. Medical hazard during previous prostatic biopsy procedures\n3. Medical hazard expected during the planned biopsy procedure\n4. Serious urine outlet-problems or risk of infections or haemorrhage", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet (only in Swedish and Norwegian)", "recruitmentStart": "2001-03-01T00:00:00.000Z", "recruitmentEnd": "2005-10-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Local or locally advanced prostate cancer, pN0, M0", "diseaseClass1": "Cancer", "diseaseClass2": "Malignant neoplasm of prostate"}}, "interventions": {"intervention": {"description": "After randomisation all patients were treated with total androgen blockade (TAB) with an LHRH-agonist (Procren Depot; Abbott), for three months in combination with an oral anti-androgen (AA) Eulexin (Schering-Plough) 250 mg x 3. Thereafter all patients continued on the anti-androgen alone, T Eulexin 250 mg x 3 daily, continuously until progression. After three months patients in the radiotherapy and hormone arm started radiotherapy whereas patients in the hormone-only arm had no local treatment. Minimal radiation dose to the prostate will be 70 Gy and the seminal vesicles will be included up to a minimum dose of 50 Gy.\n\nProstate biopsies should be taken at the 3 year (and 6 months) follow up visit.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": "Flutamide, Procren Depot, T Eulexin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder19017-0", "Funder19017-1"], "contactId": "Contact57016_19017", "sponsorId": "Sponsor55606"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact57016_19017", "title": "Dr", "forename": "Arne", "surname": "Solberg", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "St. Olavs Hospital\nKreftavdelingen\nOlav Kyrresgt. 17.", "city": "Trondheim", "country": "Norway", "zip": "7006", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55606", "organisation": "Scandinavian Prostate Cancer Group (SPCG) (Sweden)", "website": "http://www.spcg.no/", "sponsorType": "Research organisation", "contactDetails": {"address": "P.O. Hedlund\nSkogstien 22\n131 42 Nacka", "city": "Stockholm", "country": "Sweden", "zip": "103 42", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+46 (0)87 167 659"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "spcg@spcg.no"}}, "privacy": "Public"}, "funder": [{"@id": "Funder19017-0", "name": "The Nordic Cancer Union (Norway)", "fundRef": null}, {"@id": "Funder19017-1", "name": "The Norwegian Cancer Society (Norway)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2009-09-28T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2009-09-28T00:00:00.000Z", "#text": "09512688"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A First-in-Human study in healthy male volunteers to investigate the safety, tolerability and pharmacokinetics of recombinant human soluble Fc gamma receptor IIb, sFc\u03b3RIIb (SM101) administered intravenously as single ascending doses", "scientificTitle": "A First-in-Human Phase I, double-blind, randomised, placebo-controlled study in healthy male volunteers to investigate the safety, tolerability and pharmacokinetics of recombinant human soluble Fc gamma receptor IIb, sFc\u03b3RIIb (SM101) administered intravenously as single ascending doses", "acronym": null, "studyHypothesis": "The primary objective of this first-in-human study is to evaluate the safety and tolerability of escalating single doses of intravenously administered sFc\u03b3RIIb (SM101). \n\nThe secondary objective of this study is to assess the pharmacokinetic profile of sFc\u03b3IIRb (SM101) in healthy male subjects.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Safety assessments: \n1. Haematology, clinical chemistry, coagulation parameters, urinalysis (screening, day -1, pre-dose and 6, 24, 48 and 72 hours after drug administration and on days 6, 8, 12, and 15, follow-up (FU) at 6 months and FU 1 year) \n2. IL-6 and CRP (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72 hours after start of infusion and on days 6, 8, 12 and day 15, FU 6 months and FU 1 year) \n3. Vital signs, 12-lead ECG (screening, day -1, and 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration and on day 15, FU 6 months and FU 1 year) \n4. Physical examination (screening, day -1, 24 and 48 hours after drug administration and on day 4 before discharge, day 15, FU 6 months and FU 1 year) \n5. Local tolerability (day 1 at 0.25, 0.5, 1, 2, 4 and 12 hours after start of infusion, days 2 and 3 and before discharge on day 4) \n6. Adverse events (The National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v 3.0)", "secondaryOutcome": "Pharmacokinetic analysis:\nPre-dose, 0.25, 0.5, 1, 1.25, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after start of infusion", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics Committee approval was obtained from the Aerztekammer Nordrhein on 08/04/2009 (ref 2008402)"}, "externalRefs": {"doi": "10.1186/ISRCTN09512688", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "SM101-101-hv-08"}, "trialDesign": {"studyDesign": "Single-centre double-blind randomised placebo controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2009-04-30T00:00:00.000Z", "overallEndDate": "2009-10-02T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "79234c9e-e1b3-4ffd-9150-6f088687f8e2", "name": "FOCUS Clinical Drug Development GmbH", "address": null, "city": "Neuss", "state": null, "country": "Germany", "zip": "41460"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Male, Caucasian subjects aged between 18-40 years (inclusive)\n2. Healthy subjects as determined by medical history, physical examination including vital signs, electrocardiography (ECG) and clinical laboratory testing\n3. Body weight between 70-90 kg and body mass index (BMI) between 19 and 28 kg/m^2, extremes included\n4. ECG recording based on a 12-lead ECG which is normal (PR <210 ms, QRS <110 ms, QTC 380-430 ms) or contains only slight deviations deemed to be of no clinical relevance by the investigator\n5. Normal vital signs (after 5 minutes resting), blood pressure values (systolic >=100 and <=140 mmHg, diastolic >=50 and <=90 mmHg), heart rate between 40 and 90 beats per minute (bpm), body temperature <37.5\u00b0C\n6. Subjects who are able and willing to give written informed consent\n7. Normal white blood cell count, C-reactive protein (CRP) and interleukin-6 (IL-6) at screening and on the day before treatment start\n8. Subjects must be using two acceptable methods for contraception (e.g. spermicide and condom) during the study and refrain from fathering a child in the 3 months following dosing", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "40.0"}, "gender": "Male", "targetEnrolment": "42", "totalFinalEnrolment": null, "totalTarget": "42", "exclusion": "1. In the opinion of the investigator subjects with clinically significant history or presence of cardiovascular, respiratory, renal, hepatic, metabolic, endocrinological, gastrointestinal, hematological, neurological, dermatological, psychiatric diseases, cancer or other major diseases\n2. Infection or known inflammatory process\n3. Subjects with known autoimmune diseases or immunodeficiency or known family history of autoimmune diseases or immunodeficiency\n4. Clinical significant allergic disease\n5. Subjects with known serum hepatitis or who are carriers of the hepatitis B surface antigen or hepatitis C antibodies or with a positive result to the test for HIV 1/2 antibodies\n6. Subjects who have received an investigational drug and/or a vaccination within 3 months prior to start of the treatment in study and those who anticipate receipt of a vaccine within 2 months after the last dose of study drug\n7. Subjects, who have received prior treatment within 1 year with monoclonal antibodies or other biologic agents\n8. The use of any concomitant prescription or non-prescription medication within 14 days prior to the first administration of study medication until follow-up; or treatment with medication that may affect immune function (e.g. immunoglobulins, corticosteroids) within 6 months before dosing\n9. Donation of blood (>400 ml) or blood products within the last 3 months prior to admission to the clinical unit or plasmapheresis within 4 weeks prior to study start\n10. Definite or suspected personal history of adverse reactions or hypersensitivity to drugs especially to the trial compounds (E. coli-derived proteins, Tween, mannitol) or to compounds with a similar structure\n11. Subjects who drink more than 5 cups or glasses of coffee, tea and/or cola per day\n12. Subjects with a presence or history of drug and/or alcohol abuse or an average daily intake of more than 20 g alcohol per day\n13. Subjects with a positive test for alcohol or drugs at screening and on the day before treatment start\n14. Smokers of >5 cigarettes/day or equivalent\n15. Subjects who are unlikely to be compliant and attend scheduled clinic visits as required\n16. Participation in this study on a previous dose level", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2009-04-30T00:00:00.000Z", "recruitmentEnd": "2009-10-02T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Chronic Adult Idiopathic Thrombocytopenic Purpura", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Purpura and other haemorrhagic conditions"}}, "interventions": {"intervention": {"description": "sFc\u03b3RIIb (SM101) is a recombinant, soluble, non-glycosylated version of the human Fc\u03b3 receptor Fc\u03b3RIIb.\n\nSeven consecutive regular dose groups (0.004, 0.04, 0.4, 1, 2.5, 5 and 10 mg/ kg) will receive one single intravenous administration of sFc\u03b3RIIb (SM101) or placebo over 60 minutes under fasted conditions. Further 4 intermediate dose groups may be included, if deemed necessary for safety reasons. Each dose group consists of 6 subjects (4 verum, 2 placebo). Decision on dose escalation will be subject to an independent DSMB.\n\nAfter a 14-day screening period the subjects will either be enrolled in the verum or placebo arm and will be hospitalised one day before treatment start (day -1). They will be discharged 72 hours after dosing (day 4) and return to the site on day 6, 8 and 12 for ambulatory visits. The active part of the study will be completed on day 15 (conclusion visit). Subjects will attend a follow-up visit 6 months and 1 year after dosing to collect further safety data.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase I", "drugNames": "Recombinant human soluble Fc gamma receptor IIb, sFc\u03b3RIIb (SM101)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18986-0", "contactId": "Contact56985_18986", "sponsorId": "Sponsor55574"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56985_18986", "title": "Dr", "forename": "Andreas", "surname": "Schroedter", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "FOCUS Clinical Drug Development GmbH\nStresemannallee 6", "city": "Neuss", "country": "Germany", "zip": "41460", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55574", "organisation": "SuppreMol GmbH (Germany)", "website": "http://www.suppremol.com", "sponsorType": "Industry", "contactDetails": {"address": "Am Klopferspitz 19", "city": "Martinsried", "country": "Germany", "zip": "82152", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.473105.4", "rorId": "https://ror.org/05jgtkc28"}, "funder": {"@id": "Funder18986-0", "name": "German Federal Ministry of Education and Research (Bundesministerium Fur Bildung und Forschung [BMBF]) (Germany) , Grant number: 01GU0623", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-09-28T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2007-08-30T00:00:00.000Z", "#text": "90646644"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Micropulse diode vs conventional green laser treatment in clinically significant diabetic macular oedema", "scientificTitle": null, "acronym": null, "studyHypothesis": "Micropulse diode laser has been used for patients with clinically significant diabetic macular oedema. It has not been directly compared with the standard treatment with green laser. In this study, we are going to perform a prospective randomised double-masked controlled trial to compare these two treatment modalities.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Visual acuity at 12 months.", "secondaryOutcome": "The following will be assessed at 12 months: \n1. Contract sensitivity \n2. Central retinal thickness \n3. Visible laser scars in macula", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "South East London Ethical Committee, approved on 14 August 2003(ref: 07-03-159)"}, "externalRefs": {"doi": "10.1186/ISRCTN90646644", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "MP1"}, "trialDesign": {"studyDesign": "Prospective randomised double-masked controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-01-01T00:00:00.000Z", "overallEndDate": "2007-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "3d04cd91-b285-422c-b727-6d6b99776551", "name": "Laser and Retinal Research Unit", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "SE5 9RS"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients with clinically significant macular edema due to diabetes in at least one eye\n2. Able to understand and consent to the study\n3. Vision acuity on study eye better than 20/200", "ageRange": "Not Specified", "gender": "Both", "targetEnrolment": "100", "totalFinalEnrolment": null, "totalTarget": "100", "exclusion": "1. Ocular surgery within the past 6 months\n2. Any laser surgery in the study eye\n3. Any other ocular diseases in the study eye that can alter vision during the study period\n4. Poor diabetic control with HBA1c >12", "patientInfoSheet": null, "recruitmentStart": "2005-01-01T00:00:00.000Z", "recruitmentEnd": "2007-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Diabetic macular oedema", "diseaseClass1": "Eye Diseases", "diseaseClass2": "Retinal disorders in diseases classified elsewhere"}}, "interventions": {"intervention": {"description": "Micropulse diode vs conventional green laser treatment", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19054831 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "c6105862-bd96-41a4-8bf2-ccd1bcd89db9", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-10-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19054831"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder16757-0", "contactId": "Contact54715_16757", "sponsorId": "Sponsor53271"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54715_16757", "title": "Dr", "forename": "Victor", "surname": "Chong", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Laser and Retinal Research Unit\nKing's College Hospital\nDenmark Hill", "city": "London", "country": "United Kingdom", "zip": "SE5 9RS", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "victor@eretina.org"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53271", "organisation": "King's College Hospital (UK)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "Denmark Hill", "city": "London", "state": "England", "country": "United Kingdom", "zip": "SE5 9RS", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "victor.chong@kch.nhs.uk"}}, "privacy": "Public", "gridId": "grid.498493.b", "rorId": "https://ror.org/01qz4yx77"}, "funder": {"@id": "Funder16757-0", "name": "Ophthalmic Fund within the King's College Hospital NHS Trust (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-09-28T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2007-05-02T00:00:00.000Z", "#text": "88675588"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction?", "scientificTitle": "Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction? A randomised controlled trial", "acronym": "HEPRIN: HEparin for the PRevention of complications related to placental INsufficiency", "studyHypothesis": "The administration of heparin to women with identified placental dysfunction will:\n1. Reduce the risk of intra-uterine foetal death\n2. Reduce the risk of other adverse pregnancy outcomes", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Intrauterine foetal death\n2. Adverse pregnancy complications (including pre-eclampsia, preterm birth, infant small for gestational age, neonatal death)\n\nThese  will be assessed during the antenatal period (in relation to side effects of medication) and after the time of birth for birth and postpartum outcomes.", "secondaryOutcome": "1. Adverse neonatal outcomes\n2. Adverse maternal outcomes\n3. Maternal quality of life and emotional wellbeing: this will be assessed at four months postpartum using standard questionnaires (the Edinburgh depression scale; the 36-item Short Form health survey [SF-36] and the Speilberger anxiety trait questionnaires)\n4. Placental pathology\n\nThese  will be assessed during the antenatal period (in relation to side effects of medication) and after the time of birth for birth and postpartum outcomes.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Approval received from the Mount Sinai Hospital (Canada) on the 6th March 2007."}, "externalRefs": {"doi": "10.1186/ISRCTN88675588", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled open label trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-03-21T00:00:00.000Z", "overallEndDate": "2010-02-28T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Canada"}, "trialCentres": {"trialCentre": {"@id": "5c9d6f8e-d8ba-43d6-967a-668a68a04b9f", "name": "Department of Obstetrics & Gynecology", "address": null, "city": "Toronto", "state": null, "country": "Canada", "zip": "M5G 1Z4"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Women with a singleton pregnancy at 18 to 22 weeks gestation\n2. Evidence of placental dysfunction in their current pregnancy as determined by two or more of the following: \na. abnormal ultrasonographic placental morphology\nb. abnormal uterine artery Doppler waveforms\nc. one or more abnormal biochemical markers on first or second trimester maternal serum screening", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Female", "targetEnrolment": "102", "totalFinalEnrolment": null, "totalTarget": "102 women", "exclusion": "1. Women with known positive thrombophilic screening\n2. Known lethal foetal anomaly\n3. Any contraindication to heparin therapy or continuation of the pregnancy (e.g.,  chorioamnionitis requiring delivery)\n4. Clinical need for heparin therapy during pregnancy (e.g., previous venous thrombo-embolic episode)\n5. Multiple pregnancy\n6. Hypertension\n7. Language barrier requiring official translator", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2007-03-21T00:00:00.000Z", "recruitmentEnd": "2010-02-28T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Pregnancy; placental dysfunction", "diseaseClass1": "Pregnancy and Childbirth", "diseaseClass2": "Placental dysfunction"}}, "interventions": {"intervention": {"description": "Daily subcutaneous heparin (7500 units twice daily from randomisation [18 to 24 weeks gestation] until birth) versus standard care (no medication administered).\n\nFollow up was performed on women and their infants up to four months of age; longer term follow up may be possible subject to further successful funding.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Heparin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16329-0", "contactId": "Contact54286_16329", "sponsorId": "Sponsor52838"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54286_16329", "title": "Prof", "forename": "John", "surname": "Kingdom", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Obstetrics & Gynecology\n700 University Ave, 3rd Floor", "city": "Toronto", "country": "Canada", "zip": "M5G 1Z4", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "jkingdom@mtsinai.on.ca"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52838", "organisation": "University of Toronto (Canada)", "website": "http://www.utoronto.ca/", "sponsorType": "University/education", "contactDetails": {"address": "Mt Sinai Hospital\n600 University Avenue", "city": "Toronto", "country": "Canada", "zip": "M5G 1Z4", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.17063.33", "rorId": "https://ror.org/03dbr7087"}, "funder": {"@id": "Funder16329-0", "name": "The Physicians Services Incorporated Foundation (Canada)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-09-28T00:00:00.000Z", "@version": "26", "isrctn": {"@dateAssigned": "2006-04-12T00:00:00.000Z", "#text": "16772662"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Group treatment: an acceptable and effective method of physiotherapy provision for female urinary incontinence?", "scientificTitle": null, "acronym": "INCON", "studyHypothesis": "The aims of this study are to:\n1. Compare the effectiveness of group versus individual treatments in terms of quality of life and cost effectiveness in the UK health care setting\n2. Establish patients' preferences for group versus individual physiotherapy for the management of female urinary incontinence (FUI)\n3. Identify patients' concerns with regards to participation in group settings, and changes in preferences as a result of treatment", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Symptom severity questionnaire (SSI) (Black et al., 1996)\n2. Incontinence-related quality of life (IQOL) (Uebersax et al., 1995)", "secondaryOutcome": "1. Cost related to treatment attendance and complementary therapies and other products\n2. The need for further physiotherapy\n3. General practitioner (GP) utilisation and surgery will be recorded although not reported here", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "This study received an ethics approval before participant recruitment."}, "externalRefs": {"doi": "10.1186/ISRCTN16772662", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "PRF/01/2"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-08-12T00:00:00.000Z", "overallEndDate": "2005-04-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "e97ad64e-72f4-46b9-9c60-3374e0288590", "name": "University of Warwick", "address": null, "city": "Coventry", "state": null, "country": "United Kingdom", "zip": "CV4 7AL"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Females aged 18 years or over\n2. Ability to understand and capability of giving written informed consent with an interpreter if necessary\n3. Clinical symptoms of stress and/or urge incontinence", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Female", "targetEnrolment": "150", "totalFinalEnrolment": null, "totalTarget": "150", "exclusion": "1. Pregnancy\n2. Recent pelvic surgery (less than three months)\n3. History of pelvic malignancy\n4. Current urinary infection\n5. Grade III prolapse\n6. Diseases of the central nervous system (e.g. multiple sclerosis, cerebrovascular accident)\n7. Acute mental illness and dementia\n8. Previous physiotherapy for incontinence within the last 12 months", "patientInfoSheet": null, "recruitmentStart": "2002-08-12T00:00:00.000Z", "recruitmentEnd": "2005-04-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Stress incontinence and/or urge incontinence", "diseaseClass1": "Urological and Genital Diseases", "diseaseClass2": "Other disorders of urinary system"}}, "interventions": {"intervention": {"description": "Group: three group sessions for an hour each over a three-week period, with a maximum of 10 women in each treatment group.\nIndividual: an assessment given and any of the techniques used in the group sessions were taught on a one to one basis. A maximum of three sessions of 1-hour duration were permissible.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18274881 results\n2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19744315 interview study results\n2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19751517 results", "publicationStage": "Results", "biomedRelated": "true", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": [{"@id": "be7320cb-4c07-4eba-bf8a-493df0a86348", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-04-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18274881"}, "description": "results", "productionNotes": null}, {"@id": "3b093fe4-aaa6-40bf-9af5-623c686cc5ea", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-09-10T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19744315"}, "description": "interview study results", "productionNotes": null}, {"@id": "dc7d9a9f-5640-4166-a1b5-302eea3658fb", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-09-14T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19751517"}, "description": "results", "productionNotes": null}]}, "parties": {"funderId": "Funder13363-0", "contactId": "Contact50986_13363", "sponsorId": "Sponsor49378"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50986_13363", "title": "Prof", "forename": "Sarah", "surname": "Lamb", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University of Warwick\nRoom A1.04 Medical School Building\nGibbet Hill Campus", "city": "Coventry", "country": "United Kingdom", "zip": "CV4 7AL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor49378", "organisation": "Physiotherapy Research Foundation (UK)", "website": null, "sponsorType": "Charity", "contactDetails": {"address": "The Chartered Society of Physiotherapy\n14 Bedford Row", "city": "London", "country": "United Kingdom", "zip": "WC1R 4ED", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.487278.6", "rorId": "https://ror.org/04sn78z72"}, "funder": {"@id": "Funder13363-0", "name": "Physiotherapy Research Foundation (PRF) - PRF/01/2", "fundRef": null}}]}}